BioCryst Pharma (BCRX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.57 --0%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.33 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- Medline Inc. (MDLN) Reports Q3 EPS of $0.44
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
